Papyrus Therapeutics

Board of Directors

Beth Altman

Chair of the Audit Committee

  • 27+ years of experience in finance, management, business, accounting and internal controls
  • Former managing partner at KPMG LLP San Diego
  • Former KPMG LLP audit partner serving early-stage start-ups through complex public global corporations
  • Advisor to companies on capital raises, initial public offerings, M&A and corporate governance matters

Marc Beer


  • • 30+ years development and commercialization experience
  • Executive Chairman of BioTE Medical Inc
  • Founder of Renovia Inc
  • Former CEO of Aegerion Pharmaceuticals Inc (AEGR)
  • Founder of Viacell Inc (VIAC) which got sold to Perkin Elmer (PKI) Inc Beecham

Paul Blake, FRCP

Founder & CEO

  • 30+ years management and drug development experience
  • Numerous NDA/sNDA/MAA approvals, including three entirely novel indications
  • Former Chief Development Officer at Oxford Biomedica
  • Former Executive VP of Worldwide Medical and Regulatory Operations at Cephalon
  • Former Chief Medical Officer and Senior VP of Clinical R&D at SmithKline Beecham

Hani Gabra, PhD FRCP

Founder & CSO

  • Internationally-recognized translational medical oncologist and gynecologic cancer expert with 30+ years of academic experience
  • Professor Emeritus in Medical Oncology at Imperial College London
  • Visiting Professor at the Center for Cancer Biomarkers at University of Bergen
  • Former VP in early clinical development at Astra Zeneca
  • Former CMO and head of clinical development at BerGenBio AS

Jim Lorens, PhD

Chair, Scientific Advisory Board

  • 35+ years academic research and biotech industry experience across the US and Europe
  • Head of Oncology and Founding Scientist at Rigel Pharmaceuticals Inc (RIGL)
  • Founder of BerGenBio AS
  • Professor in the Department of Biomedicine at the University of Bergen Faculty of Medicine
  • Developed the first AXL targeting agent into the clinic